Clinical Trial Update: FUSION Regimen: Combined Pro re Nata and Fixed Regimen Ranibizumab in Exudative Age-related Macular Degeneration [Phase 4]

View source ↗

Summary

Phase 4 clinical trial evaluating a combined pro re nata and fixed dosing regimen of ranibizumab for exudative age-related macular degeneration has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Age-related Macular Degeneration
• Neovascular Age-related Macular Degeneration

Drugs mentioned

• Lucentis (ranibizumab)

Snippet

Sponsor: Institut de la Macula y la Retina | Conditions: Exudative Age-related Macular Degeneration | Phase 4 | Status: COMPLETED